Takeda, Wyeth Launch ENBREL Anti-Rheumatic Agent

Takeda Pharmaceutical and Wyeth jointly announced that they have begun distributing ENBREL, an injection solution for the treatment of rheumatoid arthritis (RA), March 30. ENBREL, which is currently approved in over 70 countries worldwide, is the only fully human anti-TNF receptor used as monotherapy for RA patients.

Japan Corporate News Network (http://japancorp.net/Article.Asp?Art_ID=9731)